Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Common Equity (2016 - 2025)

Cytosorbents (CTSO) has disclosed Common Equity for 14 consecutive years, with $9.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 32.6% year-over-year to $9.0 million, compared with a TTM value of $9.0 million through Sep 2025, down 32.6%, and an annual FY2024 reading of $11.1 million, down 52.7% over the prior year.
  • Common Equity was $9.0 million for Q3 2025 at Cytosorbents, down from $11.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $77.3 million in Q1 2021 and bottomed at $9.0 million in Q3 2025.
  • Average Common Equity over 5 years is $34.5 million, with a median of $24.5 million recorded in 2023.
  • The sharpest move saw Common Equity skyrocketed 262.49% in 2021, then plummeted 52.7% in 2024.
  • Year by year, Common Equity stood at $62.6 million in 2021, then plummeted by 43.47% to $35.4 million in 2022, then crashed by 33.63% to $23.5 million in 2023, then crashed by 52.7% to $11.1 million in 2024, then dropped by 18.79% to $9.0 million in 2025.
  • Business Quant data shows Common Equity for CTSO at $9.0 million in Q3 2025, $11.6 million in Q2 2025, and $14.5 million in Q1 2025.